EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response

Xue Yang, Liyuan Yin, Zhuoying Tian, Qinghua Zhou

International Journal of Molecular Sciences · 25.12.2025 · 27 (1) · 255

DOI: 10.3390/ijms27010255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.12.2025. Verfasst von Xue Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Tumor Microenvironment, Immunotherapy, Microbiota. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratumoral microbiota, once considered passive bystanders, are now recognized as active modulators of the tumor immune microenvironment (TIME)—the complex network of immune cells, stromal components, and signaling molecules within tumors—and ultimately shape immunotherapy outcomes in lung cancer. This review aims to elucidate the exact roles of intratumoral microbiota in lung cancer immuno-therapy responses and the potential mechanism, offering novel perspectives for overcoming resistance. We conducted a narrative review of the literature using a PubMed and Web of Science search of articles written in English from inception to November 2025. We summarize current evidence on the characteristics of intratumoral microbiota in lung cancer and their associations with patient outcomes following immune checkpoint inhibitor (ICI) treatment. We discuss how intratumoral microbes, their metabolites, and extracellular vesicles influence and remodel TIME, thereby either promoting or counteracting ICI efficacy. Furthermore, we explore the potential of microbial signatures as predictive biomarkers and highlight microbiota-targeted strategies—including probiotics, engineered bacteria, and rational antibiotic use—to overcome resistance and enhance clinical benefits. Collectively, available data support intratumoral microbiota as crucial modulators and promising therapeutic targets in lung cancer, and decoding their multifaceted interactions may inform precision microbiota-targeting strategies to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsTumor MicroenvironmentImmunotherapyMicrobiotaHumansAnimalsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapy resistanceintratumoral microbiotalung cancermicrobial metabolitestumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, X., Yin, L., Tian, Z., & Zhou, Q. (2025). Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response. International Journal of Molecular Sciences, 27(1), 255. https://doi.org/10.3390/ijms27010255

Vancouver

Yang X, Yin L, Tian Z, Zhou Q. Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response. International Journal of Molecular Sciences. 2025;27(1):255. doi:10.3390/ijms27010255

BibTeX
@article{Yang2025,
  author = {Yang, Xue and Yin, Liyuan and Tian, Zhuoying and Zhou, Qinghua},
  title = {Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {255},
  doi = {10.3390/ijms27010255}
}
Kostenlos starten →